Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 2873 entries
View as:

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

Phase: N/A Priority: Normal
NCT ID: NCT03460769 Org: User:
Start: 04/01/21 End: 06/30/27 Due: 06/30/28

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Phase: N/A Priority: Normal
NCT ID: NCT04739072 Org: User:
Start: 11/22/19 End: 12/31/25 Due: 12/31/26

Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells

Phase: N/A Priority: Normal
NCT ID: NCT01362452 Org: User:
Start: 12/07/12 End: 07/25/17 Due: 07/25/18

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Phase: N/A Priority: Normal
NCT ID: NCT06345495 Org: User:
Start: 10/01/24 End: 01/01/29 Due: 01/01/30

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02135874 Org: User:
Start: 10/27/14 End: 02/21/23 Due: 02/21/24

Plerixafor for Stem Cell Mobilization in Normal Donors

Phase: N/A Priority: Normal
NCT ID: NCT01818284 Org: User:
Start: 10/31/13 End: 06/30/16 Due: 06/30/17

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Phase: N/A Priority: Normal
NCT ID: NCT06087263 Org: User:
Start: 06/18/24 End: 07/01/34 Due: 07/01/35

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03579446 Org: User:
Start: 11/29/18 End: 06/15/26 Due: 06/15/27

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02696993 Org: User:
Start: 12/16/16 End: 12/31/27 Due: 12/31/28

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT00850941 Org: User:
Start: 01/26/09 End: 01/31/21 Due: 01/31/22

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03576547 Org: User:
Start: 06/26/18 End: 06/19/24 Due: 06/19/25

Tu Salud Si Cuenta Intervention in Increasing Physical Activity and Healthy Eating Among Latino Families

Phase: N/A Priority: Normal
NCT ID: NCT03199365 Org: User:
Start: 06/10/16 End: 04/30/27 Due: 04/30/28

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00669877 Org: User:
Start: 08/31/02 End: 10/31/15 Due: 10/31/16

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03830164 Org: User:
Start: 11/20/19 End: 11/02/22 Due: 11/02/23

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00485485 Org: User:
Start: 01/31/07 End: 03/31/10 Due: 03/31/11

Lacosamide in Preventing Seizures in Participants With Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT01432171 Org: User:
Start: 07/25/12 End: 06/20/17 Due: 06/20/18

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03207529 Org: User:
Start: 06/07/19 End: 12/31/23 Due: 12/31/24

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03035409 Org: User:
Start: 02/08/17 End: 02/28/26 Due: 02/28/27

Preventing Sexual Dysfunction With Aromatase Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT01603303 Org: User:
Start: 12/05/12 End: 08/11/17 Due: 08/11/18

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02891447 Org: User:
Start: 09/01/16 End: 04/11/23 Due: 04/11/24

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT02861417 Org: User:
Start: 08/05/16 End: 08/31/25 Due: 08/31/26

Spectral Diagnosis of Cutaneous Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT00476905 Org: User:
Start: 04/30/07 End: 11/20/18 Due: 11/20/19

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT00492050 Org: User:
Start: 08/02/06 End: 06/28/26 Due: 06/28/27

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01363128 Org: User:
Start: 07/12/11 End: 04/08/20 Due: 04/08/21

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01413178 Org: User:
Start: 09/30/11 End: 03/10/19 Due: 03/10/20